Operator: We have a question from Roy Buchanan with JMP.
Roy Buchanan: A couple on 235, any publications or presentations of details from the SPRINT data expected later this year?
Jay Luly: The timing on that is subject to getting presentations accepted at conferences. So, we are planning presentation of the data. So what I will say is, stay tuned on that front with regards to timing and we will certainly announce the time and place and the venue once we have been accepted for presentation.
Roy Buchanan: And then anything you can give us on the tone of the partnering discussions for 235. As you mentioned, cases that are pretty low in the U.S. at least are people waiting to see how that plays out this winter? You also mentioned regulatory uncertainty, maybe is that a gating factor anything you can tell us about that?
Jay Luly: Not in any degree of specificity, but you have hit on interesting bits that are not only on our minds, obviously partners think about these things too. Trying to exactly size what the market is and understand as clearly as they can what that regulatory pathway is. We can’t control what the infection looks like in a given season. But what we can try to do is glean clarity from regulators in terms of pathways. So, we are working on the part that we can control right now.
Roy Buchanan: And then one last one on 514, this mechanism for combination. Are you looking at things that are already out there and being tested, like just TLR random choice or are you pretty much through those already and are you looking at something completely novel? Maybe hasn’t been in the clinic, maybe even from an academic lab?
Jay Luly: We have looked at a lot of the usual suspects that are out there. I mean, obviously the TLRs are out there, people have looked at various RNAI approaches and whatnot. We haven’t grabbed onto what we think is necessarily the right mechanism yet. So we are still monitoring the field. It is a little bit frustrating, there aren’t a lot of sort of profound new steps forward in this field of HPV. So, right now, it is a little bit of a holding pattern. As I have said before, we are not going to, throw other agents in to create the triple combo. I think so we have a great deal of confidence that it is a study worth funding. So, in the meantime, we are hunting still.
Operator: Our next question comes from Akash Tewari from Jefferies.
Unidentified Analyst: Hey, this is [Amy] (Ph) on for Akash. Thanks so much for taking our questions. So the first question on EDP-323, what percent of the drug is bound to plasma protein in-vivo? And additionally, do you expect any safety risks from targeting RNA polymerization? We have seen neutropenia with lumicitabine, but no, that is a new analog, which is a little different, but would love to hear your thoughts here?
Jay Luly: Yes, I don’t recall the level of protein binding, but the ratio or the multiples of the EC90 that I quoted earlier, which were ranged between 11 and 44 fold were already adjusted for that protein binding. So, whatever the protein binding is, this is on multiples on top of that, when you look at it from a free drug perspective. And you are correct lumicitabine being a nuke, a lot of the nukes in the field had issues, nukes not uncommonly suffer or benefit from, I guess depending upon how you look at it, broad activity across other polymerases. And so still seal activity can be a problem, but EDP-323 is a non-nuke polymerase inhibitor. And so far preclinical safety was excellent and human safety in terms of safety and tolerability at least from our Phase 1 study was also very, very strong.
Unidentified Analyst: And then on 235, are there any additional data sets that a potential partner would be looking for to support a collaboration? And then when do you expect to get clarity from a regulatory perspective on path to registration?
